{
    "clinical_study": {
        "@rank": "1302", 
        "arm_group": [
            {
                "arm_group_label": "BIBF 1120 + reirradiation", 
                "arm_group_type": "Experimental", 
                "description": "2 x minimal tolerated dose BIBF 1120 per day in combination with radiotherapy (2 Gy / fraction; 36 Gy in total)"
            }, 
            {
                "arm_group_label": "reirradiation alone", 
                "arm_group_type": "Active Comparator", 
                "description": "radiotherapy (2 Gy / fraction; 36 Gy in total)"
            }
        ], 
        "brief_summary": {
            "textblock": "Patients with glioblastoma at first or second progression who have failed standard treatment\n      that must have included radiochemotherapy with temozolomide and who are a candidate for a\n      reirradiation can be included into the trial. In the phase I part the minimal tolerated dose\n      (MTD)of BIBF 1120 in combination with radiotherapy will be investigated. Subjects in phase\n      II will be randomised to receive reirradiation alone or reirradiation + 2 x MTD BIBF1120."
        }, 
        "brief_title": "NOA-12: BIBF1120 and R-RT in Glioblastoma", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Glioblastoma Multiforme", 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients with a recurrence / progression of glioblastoma either not\n             being eligible for tumour resection or having macroscopic residual tumour after\n             resection of the recurrence\n\n          -  Diagnosis of glioblastoma must be proven histologically and progress must be\n             documented by MRI. MRI images must not be older than 2 weeks before first\n             dosing/start of RT\n\n          -  Not more than two prior therapy regimens including one or two resections, one or two\n             chemotherapies (one temozolomide containing concomitant to radiotherapy) and one\n             radiotherapy (RT) for the brain tumour\n\n          -  Previous irradiation therapy of the primary tumour with a maximal dose of 60 Gy; at\n             least 8 months since the end of preirradiation\n\n          -  Candidate for reirradiation with recurrent tumour visible on MRIT1 (Gd) and with the\n             largest diameter measuring 1 cm to 5 cm\n\n          -  Informed consent\n\n          -  Age \u2265 18 years, smoking or non-smoking, of any ethnic origin\n\n          -  Karnofsky performance index (KPI) \u2265 60%\n\n          -  Neutrophile counts > 1500/\u03bcl / Platelet counts > 80.000/\u03bcl /Haemoglobin > 10 g/dl /\n             Serum creatinine < 1.5-fold upper normal range / Bilirubin, AST or ALT < 2,5-fold\n             upper normal range unless attributed to anticonvulsants / Alkaline phosphatase <\n             2,5-fold upper normal range\n\n          -  Adequate contraception\n\n          -  If on steroids, stable or decreasing treatment with steroids within 5 days before\n             treatment start\n\n        Exclusion Criteria:\n\n          -  More than one RT of brain, prior first radiotherapy with more than 60 Gy\n\n          -  Cumulative total dose on the optical chiasm >54 Gy for 2 Gy/fraction, \u03b1/\u03b2=2\n\n          -  Prior treatment with bevacizumab, iodine seeds and/or brachytherapy\n\n          -  Unable to undergo MRI\n\n          -  Past medical history of diseases with poor prognosis according to the judgement of\n             the Investigator, e.g. severe coronary heart disease, severe diabetes, immune\n             deficiency, residual deficits after stroke, severe mental retardation\n\n          -  HIV or hepatitis infection\n\n          -  Pregnancy or breast feeding\n\n          -  Treatment within any other clinical trial parallel to the treatment phase of the\n             current study or within 30 days before inclusion\n\n          -  Known coronary artery disease, significant cardiac arrhythmias or severe congestive\n             heart failure (NYHA class III - IV)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666600", 
            "org_study_id": "NONK-3/NOA-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "BIBF 1120 + reirradiation", 
                "description": "BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.", 
                "intervention_name": "BIBF 1120", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "reirradiation alone", 
                "description": "36 Gy, 2 Gy / fraction, 18 fractions", 
                "intervention_name": "radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 21, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "state": "Baden-W\u00fcrttemberg", 
                        "zip": "69120"
                    }, 
                    "name": "University Hospital Heidelberg, Department of Neurooncology"
                }, 
                "investigator": {
                    "last_name": "Wolfgang Wick, Prof. Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "state": "Baden-W\u00fcrttemberg", 
                        "zip": "69120"
                    }, 
                    "name": "University Hospital Heidelberg, Department of Pharmacology"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I/II, Randomized, Open-label, Multi-centre Study of BIBF1120 + Reirradiation (R-RT) Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma", 
        "overall_contact": {
            "email": "wolfgang.wick@med.uni-heidelberg.de", 
            "last_name": "Wolfgang Wick, Prof. Dr.", 
            "phone": "0049 6221 56", 
            "phone_ext": "7337"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximal tolerated dose of BIBF 1120 in combination with reirradiation (Phase I)", 
            "safety_issue": "Yes", 
            "time_frame": "day 0, 8, 15 and 17 post-dose during phase I"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666600"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital Heidelberg", 
            "investigator_full_name": "Prof. Dr. Wolfgang Wick", 
            "investigator_title": "Professor Dr. med.", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability of BIBF1120", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 90 days follow-up"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Time from randomization until death or disease progression"
            }, 
            {
                "measure": "Objective response rates (OR)", 
                "safety_issue": "No", 
                "time_frame": "Time from randomization until response"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Time from randomization until death"
            }, 
            {
                "measure": "Quality of life as determined by EORTC QLQ-C15 PAL and the EORTC brain module QLQ-BN 20", 
                "safety_issue": "Yes", 
                "time_frame": "Screening and 6-weekly after radiotherapy"
            }, 
            {
                "measure": "Cognitive function determined by MMSE", 
                "safety_issue": "Yes", 
                "time_frame": "Screening and 6-weekly after end of radiotherapy"
            }
        ], 
        "source": "University Hospital Heidelberg", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Prof. Dr. Wolfgang Wick", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}